Advertisement

Uptake of noninvasive prenatal testing at a large academic referral center

      Objective

      Noninvasive prenatal testing (NIPT) is a recently developed risk-assessment technique with high sensitivity and specificity for fetal aneuploidy. The effect NIPT has had on traditional screening and diagnostic testing has not been clearly demonstrated. In this study, NIPT uptake and subsequent changes in the utilization of first-trimester screen (FTS), chorionic villus sampling (CVS), and amniocentesis in a single referral center is reported.

      Study Design

      Monthly numbers of NIPT (in high-risk patients), FTS, CVS, and amniocentesis were compared between a 35-month baseline period (April 2009 through February 2012) before introduction of NIPT, and the initial 16 months following NIPT introduction divided in 4-month quarters beginning in March 2012 through June 2013.

      Results

      A total of 1265 NIPT, 6637 FTS, 251 CVS, and 1134 amniocentesis were recorded over the 51-month study period in singleton pregnancies of women who desired prenatal screening and diagnostic testing. NIPT became the predominant FTS method by the second quarter following its introduction, increasing by 55.0% over the course of the study period. Total first-trimester risk assessments (NIPT+FTS) were not statistically different following NIPT (P = .312), but average monthly FTS procedures significantly decreased following NIPT introduction, decreasing by 48.7% over the course of the study period. Average monthly CVS and amniocentesis procedures significantly decreased following NIPT introduction, representing a 77.2% and 52.5% decrease in testing, respectively. Screening and testing per 100 morphological ultrasounds followed a similar trend.

      Conclusion

      NIPT was quickly adopted by our high-risk patient population, and significantly decreased alternate prenatal screening and diagnostic testing in a short period of time.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bianchi D.W.
        • Prosen T.
        • Platt L.D.
        • et al.
        Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma.
        Obstet Gynecol. 2013; 121: 1057-1062
        • Norton M.E.
        • Brar H.
        • Weiss J.
        • et al.
        Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18.
        Am J Obstet Gynecol. 2012; 207: 137.e1-137.e8
        • Palomaki G.E.
        • Deciu C.
        • Kloza E.M.
        • et al.
        DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study.
        Genet Med. 2012; 14: 296-305
        • American College of Obstetricians and Gynecologists
        Noninvasive prenatal testing for fetal aneuploidy. ACOG Committee opinion no. 545.
        Obstet Gynecol. 2012; 120: 1532-1534
        • Benn P.
        • Borell A.
        • Chiu R.
        • et al.
        Position statement from the aneuploidy screening committee on behalf of the board of the International Society for Prenatal Diagnosis.
        Prenat Diagn. 2013; 33: 622-629
        • Wilson K.L.
        • Czerwinski J.L.
        • Hoskovec J.M.
        • et al.
        NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy.
        J Genet Couns. 2013; 22: 4-15
        • Wald N.J.
        • Rodeck C.
        • Hackshaw A.K.
        • et al.
        First and second trimester antenatal screening for Down's syndrome: the results of the serum, urine and ultrasound screening study (SURUSS).
        Health Technol Assess. 2003; 7: 1-77
        • Malone F.D.
        • Canick J.A.
        • Ball R.H.
        • et al.
        First-trimester or second-trimester screening, or both, for Down's syndrome.
        N Engl J Med. 2005; 353: 2001-2011
        • Modell B.
        Chorionic villus sampling: evaluating safety and efficacy.
        Lancet. 1985; 1: 737-740
        • Skirton H.
        • Patch C.
        Factors affecting the clinical use of non-invasive prenatal testing: a mixed methods systematic review.
        Prenat Diagn. 2013; 33: 532-541
        • Walsh J.M.
        • Goldberg J.D.
        Fetal aneuploidy detection by maternal plasma DNA sequencing: a technology assessment.
        Prenat Diagn. 2013; 33: 514-520
        • Chetty S.
        • Garabedian M.J.
        • Norton M.E.
        Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening.
        Prenat Diagn. 2013; 33: 542-546
        • Kollmann M.
        • Haeusler M.
        • Haas J.
        • Csapo B.
        • Lang U.
        • Klaritsch P.
        Procedure-related complications after genetic amniocentesis and chorionic villus sampling.
        Ultraschall Med. 2013; 34: 345-348
        • Tabor A.
        • Vestergaard C.H.
        • Lidegaard O.
        Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study.
        Ultrasound Obstet Gynecol. 2009; 34: 19-24
        • Swanson A.
        • Sehnert A.J.
        • Bhatt S.
        Non-invasive prenatal testing: technologies, clinical assays and implementation strategies for women's healthcare practitioners.
        Curr Genet Med Rep. 2013; 1: 113-121
        • Taylor J.B.
        • Chock V.Y.
        • Hudgins L.
        NIPT in a clinical setting: an analysis of uptake in the first months of clinical availability.
        J Genet Couns. 2014; 23: 72-78
        • Bianchi D.W.
        • Parker R.L.
        • Wentworth J.
        • et al.
        DNA sequencing versus standard prenatal aneuploidy screening.
        N Engl J Med. 2014; 370: 799-808